CASE REPORT article
Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1586349
This article is part of the Research TopicBalancing Alloantigen-Induced Immune Responses and Anti-tumor Immunity in TransplantationView all 13 articles
CD19 CAR-T cells derived from Recipient of Umbilical Cord Blood Transplantation(UCBT) Effectively Treated Relapsed Acute Lymphoblastic Leukemia after UCBT
Provisionally accepted
- 1Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou, China
- 2Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian Province, China
- 3Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The recent advance of the chimeric antigen receptor provides an alternative approach for treating relapsed acute lymphocyte leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, relapsed patients who had undergone allogeneic umbilical cord blood transplantation (UCBT) have no chance of having CAR-T cells derived from donors due to lacking UCB.We present a case of a patient with Ph+ ALL who relapsed after UCBT and achieved complete morphological and molecular remission following treatment with CD19 CAR-T cells derived from the recipient post-UCBT."The patient only had grades I CRS. GVHD and neurotoxicity were not observed. Following more than 6 years after CAR-T cells infusion, the patient was still in hematologic and molecular complete remission with negative minimal residual disease (MRD). This case firstly showed a new strategy of practicality, efficacy and safety of CD19 CAR-T cells made from UCBT recipient for treating relapsed ALL after UCBT.
Keywords: chimeric antigen receptor T (CAR-T), Relapsed acute lymphoblastic leukemia, allogeneic umbilical cord blood transplantation (UCBT), Ph+ acute lymphoblastic leukemia, umbilical cord-derived CAR-T therapy
Received: 02 Mar 2025; Accepted: 10 Apr 2025.
Copyright: © 2025 Li, Li, Xian, Huang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nainong Li, Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.